Navidea Biopharmaceuticals Names Cutler to Board of Directors
3 December 2018 - - US-based precision immunodiagnostic agents and immunotherapeutics developer Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) has appointed Adam Cutler to the company's board of directors, the company said.

Adam Cutler joined Molecular Templates, Inc. as its chief financial officer in November 2017.

Prior, he was senior vice president of Corporate Affairs for Arbutus Biopharma Corp., where he was responsible for investor relations and contributed to the company's business development and corporate finance efforts from March 2015 to November 2017.

From 2012 to 2015, he was a managing director for The Trout Group LLC and Trout Capital LLC, where he executed financings and advised public and private life science companies on investor relations and capital raising strategies.

From 2000 to 2012, Cutler worked as a biotechnology equity research analyst with Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Securities.

He also worked in healthcare consulting as an Analyst at The Frankel Group and a Consultant for Ernst and Young LLP. He currently serves on the board of directors for Inmed Pharmaceuticals. He earned his Bachelor of Arts degree in Economics from Brandeis University.

Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment.

Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.

The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.

The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the company's pipeline through global partnering and commercialisation efforts.